Bristol-Myers Squibb Co. has agreed to pay $5.3 billion to acquire former Eli Lilly and Co. partner Amylin Pharmaceuticals Inc., a maker of diabetes therapies. The deal is valued at about $7 billion, which includes Amylin’s debt and a payment to Eli Lilly and Co. of about $1.7 billion.
The New Jersey-based pharmaceutical research company is seeking state and local incentives as part of the expansion, which would include a new laboratory, set to be finished in 2016. Covance already employs 565 workers at the site.
The Supreme Court is expected to rule on the Affordable Care Act by the end of June. Here’s a roundup of how health care businesses would be affected under four different scenarios.
If approved for acute coronary syndrome, Xarelto would compete with Effient from Indianapolis-based Eli Lilly and Co and Brilinta from London-based AstraZeneca Plc.
The city of Indianapolis granted preliminary approval for an eight-year tax abatement to Arcamed Inc., which plans to purchase $1.4 million in equipment to design and manufacture titanium and case-tray systems for surgical instruments.
The local pharmaceutical giant plans to complete the program started in 2000 by repurchasing $420 million in shares by the end of the year. And on Tuesday, it declared a regular dividend of 49 cents.
Republicans in the U.S. House joined with 37 Democrats to pass a bill repealing a medical-device tax, chipping away at the 2010 health-care law in a victory for companies including Indiana-based Zimmer Holdings Inc. and Boston Scientific Corp.
The Warsaw area is well-known as the home of gigantic orthopedic implant companies and their suppliers. But now a handful of startups have been able to raise nearly $25 million in equity investments despite the recession—putting a bit more fuel into a fairly stagnant entrepreneurial sector.
Raising good cholesterol, a goal pursued by Eli Lilly and Co. as the next milestone in cardiac care, may not cut heart-attack risk, says a study that challenges the development of drugs that may someday generate billions of dollars in sales.
Eli Lilly and other big pharmaceutical companies are creating thousands of research jobs overseas as countries led by Singapore, Ireland and South Africa boost incentives.
Indianapolis-based Eli Lilly and Co. and London-based AstraZeneca Plc aren't expected to have an easier time gaining more of the market for blood thinners dominated by Bristol-Myers Squibb Co.’s Plavix after the drug loses U.S. patent protection Thursday.
Treatments for central nervous system diseases have a huge potential payoff, analysts say. A hint of whether the gamble may pay off is due in the second half of this year, as Eli Lilly and Co. and Pfizer Inc. announce results for Alzheimer’s drugs that attack the same protein as Roche’s experimental drug.
A second experimental cholesterol medicine in a once-promising class of drugs meant to replace blockbusters such as Lipitor has failed in testing, casting doubt on whether any of the drugs will ever make it to pharmacies. Eli Lilly is developing a similar drug.
The health care company that once promised to create 900 jobs in central Indiana has agreed to cease operations after a major lender moved to foreclose on the struggling Indianapolis-based business.
Authorities have arrested two Cuban brothers in the 2010 theft of about $80 million in Eli Lilly and Co. prescription drugs from a Connecticut warehouse, a robbery described as one of the biggest pharmaceutical heists in history, the U.S. attorney’s office said Thursday.
More than 20 compounds that Eli Lilly and Co., Pfizer Inc. and AstraZeneca Plc failed to turn into drugs will be tested by U.S.-sponsored scientists in a $20 million program to see if they’ll work against ailments they weren’t aimed at previously.
The market for testosterone-replacement treatments is growing, but health experts say overuse of the drugs can be dangerous.
A Vivus Inc. pill that is supposed to provide erections within 15 minutes, about half the time or less than Eli Lilly and Co.'s Cialis or Pfizer Inc.’s Viagra, has received U.S. regulatory approval.
Lilly’s quarterly sales and profit fell due to lost patent protection on Gemzar and Zyprexa. But sales of antidepressant Cymbalta, blood thinner Effient, animal health products and sales in China grew by 20 percent or more.
Seventy-two employees will lose their jobs when the 32-bed long-term-care facility shuts down on June 17. The company that operates the hospital did not provide a reason for the closing.
